Defendants in Tuschl-I IP Suit Cast Doubt on Claims of Pending Patent Issuance
July 16, 2009
Defendants in Tuschl-I IP Suit Cast Doubt on Claims of Pending Patent Issuance
In doing so, the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology, and the University of Massachusetts have all asked that the court reject Alnylam Pharmaceuticals and Max Planck's request for an order blocking any Tuschl-I patent issuance.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Ongoing Tuschl IP Row, USPTO OKs Planck’s Request to Pull Power of Attorney from Whitehead
September 17, 2009 / Gene Silencing News - Court Denies Alnylam, Max Planck’s Request to Block Tuschl-I IP Prosecution in US
September 3, 2009 / Gene Silencing News - Max Planck, Alnylam Attorneys Argue UMass Letter Shows Max Planck Owns Tuschl-II Inventions
August 6, 2009 / Gene Silencing News - Timeline of Events Leading to Tuschl IP Litigation
January 28, 2010 / Gene Silencing News - UMass, Whitehead Fire New Salvo in Tuschl IP Suit, Claim Max Planck Meddled with Power of Attorney
August 27, 2009 / Gene Silencing News